Eye implant approved by Scottish Medicines Consortium

Article

Ozurdex has been accepted by the Scottish Medicines Consortium for use within the NHS in Scotland.

Ozurdex has been accepted by the Scottish Medicines Consortium for use within the NHS in Scotland.

Allergan announced the approval of the dexamethasone intravitreal implant for patients with macula oedema following central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

In a trial of 1000 patients Ozurdex was proven to increase vision by 15 letters or more on an eye chart in 29% of macular oedema patients. Some patients experienced these improvements for up to six months.

Patients in England and Wales already had access to Ozurdex, meaning the decision is important for Scottish macula oedema sufferers. Consultant ophthalmologist surgeon, Forth Valley NHS Trust, Mr Tariq Saboor, said, "The availability of a licensed, effective and now SMC accepted treatment is a significant step forward for management of RVO patients in Scotland. Having access to a treatment that tackles the significant inflammation and swelling resulting from blocked retinal veins is good news for my patients. The fact that the treatment only needs to be administered up to every 6 months is also a significant advantage.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
Related Content
© 2025 MJH Life Sciences

All rights reserved.